1.74 (0.01%)
As of Jan 14, 2022
Source:
We are a clinical-stage biotechnology company that uses our proprietary gene therapy platform technology to develop transformational genetic therapies for people suffering from rare and debilitating diseases. Our initial focus is in the field of ophthalmology, where we have wholly owned clinical-stage programs in X-linked retinitis pigmentosa (“XLRP”) and achromatopsia (“ACHM”), and an optogenetics program through our collaboration with Bionic Sight, Inc. (“Bionic Sight”).
Country | United States |
Headquarters | alachua, florida |
Phone Number | 386-462-2204 |
Industry | manufacturing |
CEO | Susan B. Washer |
Website | agtc.com |